Market Overview:
The global low molecular heparin preparation market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of venous thromboembolism (VTE) and rising demand for low molecular weight heparins (LMWHs). LMWHs are preferred over unfractionated heparin (UFH) due to their improved safety and efficacy profiles. Based on type, the global low molecular heparin preparation market is segmented into enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Enoxaparin sodium dominates the market owing to its high efficacy and safety profile. Nadroparin calcium is expected to grow at a higher CAGR during the forecast period as it offers several benefits such as easy availability and lower cost than other LMWHs products available in the market. Dalteparin sodium held a minor share of the global low molecular weight heparin preparations market in 2017 due its high cost compared with other LMWH products available in the market.
Product Definition:
Low Molecular Heparin Preparation is a drug used to prevent and treat blood clots. It works by blocking the formation of new blood clots and breaking up existing ones.
Enoxaparin Sodium:
Enoxaparin sodium is a type of low molecular heparin (LMH) which is used to treat deep vein thrombosis and pulmonary embolism. It's the active ingredient in Jantoven, a medicine prescribed for prevention from venous thromboembolism (VTE) in patients with cancer who are undergoing chemotherapy or radiation therapy.
Nadroparin Calcium:
Nadroparin calcium is a form of low molecular weight heparin. It is used in the treatment of deep vein thrombosis and pulmonary embolism.
Application Insights:
Based on the application, the global low molecular heparin preparation market is segmented into hospital and pharmacy. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as increasing number of surgeries, growing geriatric population, and rising prevalence of chronic diseases. As per WHO¢â‚¬â„¢s estimates, there will be approximately 1.7 billion people aged 60 years or above by 2030 globally which is expected to contribute significantly towards growth over the forecast period.
Pharmacy also accounted for a significant share owing to factors such as increasing awareness about cost-effectiveness along with favorable reimbursement policies that encourage adoption of low molecular heparin preparations over conventional ones in various countries including Germany, Japan etc., throughout 2018 and 2019 respectively by Nihon Unilever Ltd., Pfizer India Pvt. Ltd., Merck KGaA Darmstadt GmbH & Co.
Regional Analysis:
North America dominated the global low molecular heparin preparation market in 2016 with a revenue share of over 35%. This is due to the presence of well-established healthcare infrastructure, high per capita income, and rising incidence of cardiovascular diseases. Moreover, increasing use of advanced medical products for therapeutic and diagnostic purposes is anticipated to drive regional growth.
Asia Pacific region is expected to witness lucrative growth during the forecast period owing to improving healthcare facilities & infrastructure along with growing target population in emerging countries such as China & India. In addition, economic development coupled with rising disposable income will boost demand for these products over the forecast period. Furthermore, favorable regulatory reforms are also expected to contribute towards industry expansion during this period.
Growth Factors:
- Increasing incidence of venous thromboembolism (VTE) and pulmonary embolism (PE)
- Growing demand for low molecular weight heparins as prophylaxis against VTE in surgical patients
- Rising geriatric population susceptible to VTE and PE
- Increasing use of low molecular weight heparins in cancer patients for prophylaxis against tumor metastasis
- Technological advancements in low molecular weight heparin preparation
Scope Of The Report
Report Attributes
Report Details
Report Title
Low Molecular Heparin Preparation Market Research Report
By Type
Enoxaparin Sodium, Nadroparin Calcium, Dalteparin Sodium
By Application
Hospital, Pharmacy
By Companies
Hepalink, King-friend Biochemical Pharmaceutical, Dongcheng Biochemicals, Changshan Pharm, Pfizer, Qianhong Bio-pharma, Tiandong, Xinbai, Sanofi, Aspen (N.V.Organon), GlaxoSmithKline, Zhaoke Pharmaceutical, ALFA WASSERMANN, Qilu Pharmaceutica, Jiangsu Da Lian Pharmaceutical, Hangzhou Jiuyuan Gene Engineering, Tianjin Chase Sun Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Low Molecular Heparin Preparation Market Report Segments:
The global Low Molecular Heparin Preparation market is segmented on the basis of:
Types
Enoxaparin Sodium, Nadroparin Calcium, Dalteparin Sodium
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hepalink
- King-friend Biochemical Pharmaceutical
- Dongcheng Biochemicals
- Changshan Pharm
- Pfizer
- Qianhong Bio-pharma
- Tiandong
- Xinbai
- Sanofi
- Aspen (N.V.Organon)
- GlaxoSmithKline
- Zhaoke Pharmaceutical
- ALFA WASSERMANN
- Qilu Pharmaceutica
- Jiangsu Da Lian Pharmaceutical
- Hangzhou Jiuyuan Gene Engineering
- Tianjin Chase Sun Pharmaceutical
Highlights of The Low Molecular Heparin Preparation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enoxaparin Sodium
- Nadroparin Calcium
- Dalteparin Sodium
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Low Molecular Heparin Preparation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Low molecular heparin preparations are made from heparin fragments that have been cut down to a length of less than 100 amino acids. This makes them more stable and easier for the body to absorb.
Some of the major players in the low molecular heparin preparation market are Hepalink, King-friend Biochemical Pharmaceutical, Dongcheng Biochemicals, Changshan Pharm, Pfizer, Qianhong Bio-pharma, Tiandong, Xinbai, Sanofi, Aspen (N.V.Organon), GlaxoSmithKline, Zhaoke Pharmaceutical, ALFA WASSERMANN, Qilu Pharmaceutica, Jiangsu Da Lian Pharmaceutical, Hangzhou Jiuyuan Gene Engineering, Tianjin Chase Sun Pharmaceutical.
The low molecular heparin preparation market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Low Molecular Heparin Preparation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Low Molecular Heparin Preparation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Low Molecular Heparin Preparation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Low Molecular Heparin Preparation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Low Molecular Heparin Preparation Market Size & Forecast, 2018-2028
4.5.1 Low Molecular Heparin Preparation Market Size and Y-o-Y Growth
4.5.2 Low Molecular Heparin Preparation Market Absolute $ Opportunity
Chapter 5 Global Low Molecular Heparin Preparation Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Low Molecular Heparin Preparation Market Size Forecast by Type
5.2.1 Enoxaparin Sodium
5.2.2 Nadroparin Calcium
5.2.3 Dalteparin Sodium
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Low Molecular Heparin Preparation Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Low Molecular Heparin Preparation Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Low Molecular Heparin Preparation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Low Molecular Heparin Preparation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Low Molecular Heparin Preparation Analysis and Forecast
9.1 Introduction
9.2 North America Low Molecular Heparin Preparation Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Low Molecular Heparin Preparation Market Size Forecast by Type
9.6.1 Enoxaparin Sodium
9.6.2 Nadroparin Calcium
9.6.3 Dalteparin Sodium
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Low Molecular Heparin Preparation Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Low Molecular Heparin Preparation Analysis and Forecast
10.1 Introduction
10.2 Europe Low Molecular Heparin Preparation Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Low Molecular Heparin Preparation Market Size Forecast by Type
10.6.1 Enoxaparin Sodium
10.6.2 Nadroparin Calcium
10.6.3 Dalteparin Sodium
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Low Molecular Heparin Preparation Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Low Molecular Heparin Preparation Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Low Molecular Heparin Preparation Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Low Molecular Heparin Preparation Market Size Forecast by Type
11.6.1 Enoxaparin Sodium
11.6.2 Nadroparin Calcium
11.6.3 Dalteparin Sodium
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Low Molecular Heparin Preparation Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Low Molecular Heparin Preparation Analysis and Forecast
12.1 Introduction
12.2 Latin America Low Molecular Heparin Preparation Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Low Molecular Heparin Preparation Market Size Forecast by Type
12.6.1 Enoxaparin Sodium
12.6.2 Nadroparin Calcium
12.6.3 Dalteparin Sodium
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Low Molecular Heparin Preparation Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Low Molecular Heparin Preparation Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Low Molecular Heparin Preparation Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Low Molecular Heparin Preparation Market Size Forecast by Type
13.6.1 Enoxaparin Sodium
13.6.2 Nadroparin Calcium
13.6.3 Dalteparin Sodium
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Low Molecular Heparin Preparation Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Low Molecular Heparin Preparation Market: Competitive Dashboard
14.2 Global Low Molecular Heparin Preparation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hepalink
14.3.2 King-friend Biochemical Pharmaceutical
14.3.3 Dongcheng Biochemicals
14.3.4 Changshan Pharm
14.3.5 Pfizer
14.3.6 Qianhong Bio-pharma
14.3.7 Tiandong
14.3.8 Xinbai
14.3.9 Sanofi
14.3.10 Aspen (N.V.Organon)
14.3.11 GlaxoSmithKline
14.3.12 Zhaoke Pharmaceutical
14.3.13 ALFA WASSERMANN
14.3.14 Qilu Pharmaceutica
14.3.15 Jiangsu Da Lian Pharmaceutical
14.3.16 Hangzhou Jiuyuan Gene Engineering
14.3.17 Tianjin Chase Sun Pharmaceutical
